Depletion of both CD8+ and CD4+ T cells completely abolished the anti-primary and -rechallenged tumor responses elicited by the in situ cancer vaccine, while depletion of either cell type caused only a modest reduction (Fig. 7B, C). The gene discussed is CD8A; the disease is cancer.